Results 171 to 180 of about 25,638 (254)

Commentary on: Genetic predictors of GLP1 receptor agonist weight loss and side effects (Nature volume 653, pages 770–775 (2026))

Journal of Diabetes Investigation, EarlyView.
Gotaro Toda, Toshimasa Yamauchi
wiley   +1 more source

Microbiome and Metabolomics in Obesity: Advances in Understanding and Interventions Across the Lifespan

Obesity Reviews, EarlyView.
ABSTRACT Obesity arises from intertwined and reciprocal diet‐microbiome‐host pathways that reshape energy balance, insulin sensitivity, and inflammation. This review synthesizes mechanistic links between microbial functions and metabolic control, charts lifestyle‐related lifecourse dynamics from birth to older age, examines how GLP‐1‐based therapies ...
Ioanna Panagiota Kalafati, David Krongauz, Alice Bosco, Antonio Noto, Cristina Piras, Maria Kafyra, Angelica Dessì, Matteo Mauri, Luigi Atzori, Adina Weinberger, Vassilios Fanos, George V. Dedoussis, on behalf of the BETTER4U consortium   +12 more
wiley   +1 more source

Current and forthcoming pharmacotherapies for adolescent obesity: Evidence-based review. [PDF]

World J Clin Pediatr
Fuentes-Mendoza JM, Concepción-Zavaleta MJ, Dongo-Dueñas LG, Jara-Pianto JMJ, Sierra-Martel JA, Medina-Angulo CA, Virú-Flores HM, Mendoza-Godoy JJ, Zavaleta-Gutiérrez FE, Paz-Ibarra J.   +9 more
europepmc   +1 more source

Toward “Obesityomics”: Domain‐Specific Omics in Precision Obesity Medicine with a Brief AI Perspective

Obesity Reviews, EarlyView.
ABSTRACT Background Obesity's global rise has outpaced the effectiveness of “one‐size‐fits‐all” prevention and treatment strategies. The promise of precision medicine lies in addressing the etiological and biological diversity of obesity and transforming it into actionable endotypes.
Nadia Abu Samra, Sara G. I. Suliman, Mohammed Al‐Hadad, Dorret I. Boomsma, Fadwa Alhantoobi, Maithah Alsamahi, Haneen Abufarajallah, Alia Al Tikriti, Zeyar Aung, Selena Richards, Abdulrahim Sajini, Mira Mousa, Fatima Sulaiman, Wael Osman   +13 more
wiley   +1 more source

Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists. [PDF]

Cells
Melnikov I, Borodko D, Alekseev V.
europepmc   +1 more source

Exploring lifestyle management in polycystic ovary syndrome through implementation frameworks

Experimental Physiology, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome [PMOS; previously known as polycystic ovary syndrome (PCOS)] is an endocrine condition affecting 10%–13% of women of reproductive age, with cardiometabolic, reproductive and psychological features. The PMOS guidelines have established recommendations for its management, which can include pharmacological,
Margaret McGowan, Stephanie Cowan, Chau Thien Tay, Lisa J. Moran, Ashley H. Ng   +4 more
wiley   +1 more source

Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Santos-Pereira M, Frutuoso JF, Pereira SS, Guimarães M, Monteiro MP.   +4 more
europepmc   +1 more source

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment. [PDF]

Int J Mol Sci
Anastasiou IA, Tentolouris K, Katsaouni A, Sarantis P, Mourouzis I, Rebelos E, Tentolouris N.   +6 more
europepmc   +1 more source

Fragment Coverage: Unified Visualization and Quantitative Assessment of MS/MS Fragmentation Supports Metabolite Identification in Macromolecule Drug Metabolism Studies

Rapid Communications in Mass Spectrometry, Volume 40, Issue 21, 15 November 2026.
ABSTRACT Rationale Peptides and oligonucleotides are increasingly used as therapeutic agents, making the identification and structural elucidation of their metabolites a critical step in drug development. Liquid chromatography–mass spectrometry (LC‐MS/MS) is the primary analytical technique for this purpose; however, extensive backbone fragmentation ...
Paula Cifuentes, Albert Garriga, Fabien Fontaine, Ismael Zamora   +3 more
wiley   +1 more source